Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more ...
HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback